Risk factors
Neurogene (NGNE) risk factors
Item 1A of every Neurogene Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors64 risks1 new2 dropped18 reworded
Neurogene added healthcare reform risks and warned of potential U.S. tariffs on imported pharmaceuticals.
Filed Mar 24, 2026 - FY2024 10-K risk factors65 risks
Company is a clinical-stage biotechnology firm with cumulative net losses of $262.3 million from inception through December 31, 2024. Operations are heavily dependent on the lead gene therapy candidate NGN-401 using AAV9 delivery. The portfolio faces intense intellectual property protection needs and manufacturing complexities at its Houston facility.
Filed Mar 24, 2025